Faron Pharmaceuticals Presents Results from PD-1 Blockade Refractory Melanoma Cohort of MATINS Trial at 19th International Congress of The Society for Melanoma Research
Faron Pharmaceuticals Ltd. (“Faron or Company”) Faron Pharmaceuticals Presents Results from PD-1 Blockade Refractory Melanoma Cohort of MATINS Trial at 19th International Congress of The Society for Melanoma Research · 100% overall survival at 12-months in PD-1 blockade refractory melanoma patients who experienced clinical benefit from bexmarilimab · Patients with cold tumors, defined by low baseline levels of pro-inflammatory cytokines, were more likely to experience clinical benefit following treatment with bexmarilimab · Patients who experienced clinical